Balkrishna Jahagirdar

Author

Regions Hospital

Also Known As

B JAHAGIRDAR, BALKRISHNA N. JAHAGIRDAR, Balkrishna Jahagirdar, Balkrishna N Jahagirdar, Balkrishna N. Jahagirdar

Publications

Citations

H-Index

Concepts

All Affiliations

Regions Hospital University of Minnesota HealthPartners University of Minnesota Medical Center Fox Chase Cancer Center

About

Balkrishna Jahagirdar is an author at Regions Hospital specializing in medicine, health sciences, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	7.3K
2	Health Sciences	6	6	7.2K
3	Nursing	1	1	21
4	Public Health	1	1	24
5	Blood Transplantation	1	1	21

Balkrishna Jahagirdar

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow Yuehua Jiang, Balkrishna Jahagirdar, R. Lee Reinhardt, Nature Regenerative MedicineMesenchymal Stem CellsInduced Pluripotent Stem CellDevelopmental BiologyAdult Marrow	2002	5.5K
Origin of endothelial progenitors in human postnatal bone marrow Morayma Reyes, Arkadiusz Z. Dudek, Balkrishna Jahagirdar, Journal of Clinical Investigation	2002	1.1K
Origin of endothelial progenitors in human postnatal bone marrow Morayma Reyes, Arkadiusz Z. Dudek, Balkrishna Jahagirdar, Journal of Clinical Investigation Adult Stem CellStem Cell BiologyTumor BiologyTumor AngiogenesisRegenerative Medicine	2002	889
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, The Lancet Oncology OncologyIpilimumab TreatmentClinical TrialsMetastatic SarcomaAlliance A091401	2018	716
Origin of endothelial progenitors in human postnatal bone marrow Morayma Reyes, Arkadiusz Z. Dudek, Balkrishna Jahagirdar, Journal of Clinical Investigation	2002	113
Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors Navneet S. Majhail, Elizabeth Murphy, Purushottam W. Laud, Haematologica	2018	59
Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia Kebede Hussein, Balkrishna Jahagirdar, Pankaj Gupta, American Journal of Hematology	2008	53
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Anthony J. Cmelak, Shuli Li, Shanthi Marur, Journal of Clinical Oncology Surgical OncologyPathologyTreatment ResistanceCancer-associated VirusOncology	2014	50
Quantification of pain in sickle mice using facial expressions and body measurements Aditya M. Mittal, Mihir Gupta, Yann Lamarre, Blood Cells Molecules and Diseases Pain SyndromeHealth SciencesBody MeasurementsNeurophysiologyNeuroanatomy	2015	29
E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). Shanthi Marur, Shuli Li, Anthony J. Cmelak, Journal of Clinical Oncology Surgical OncologyPathologyCancer-associated VirusRadiation MedicineOncology	2013	26

Page 1